





HAIMA BIOTECH SPAC



THE HAIMA BIOTECH

	Industry	BIOTECH
	IPO Target	USD 150.000.000
	Pre-IPO Investment	USD 8.000.000
	Thereof committed	No commitments yet
	Status	In preparation

Description:


The HAIMA BIOTECH SPAC will acquire one or more forward-looking companies in the areas of

- Microbiome Therapeutics,
- Diagnostics, Devices, Analytics and/or
- Pre & Probiotics, Nutrition & Diet,

with a strong focus on own research and development.

MARKETS RIPE FOR ACQUISITIONS

High growth market segments in biotech, pharma & health-tech



Our strategy is to make selective acquisitions in the healthcare space.

As the healthcare market is large and diverse, we will focus on the above segments while keeping open for opportunistic acquisitions in other segments.

The strategy is clearly to acquire companies that will provide us access to the entire value chain from product development to distribution in that segment.


We have a clear focus to leverage analytics and insights gathered by the operating companies to systematically provide incremental value to all the operating companies.

MICROBIOME

MICROBIOME MARKET

Human microbiome is collectively all the microbes in the human body (good & bad microbes).


Disbalance (dysbiosis) between good & bad microbes is **the cause of many diseases** like cancer, atherosclerosis, diabetes, obesity etc.




$$\text{DISEASES} = \frac{\text{GOOD MICROBES}}{\text{BAD MICROBES}}$$

Addressable Market	USD 2.2bn 2020
Key Markets	US followed by EU
CAGR	9.8%
Growth Driver	<ul style="list-style-type: none">• Rising incidence of lifestyle-related diseases like CVD, Diabetes, IBS• Personalized nutrition awareness• Increase in autoimmune disorders and antibiotic resistance


MICROBIOME MARKET



CURRENT MARKET




CAGR



2024

- Market focused on technological advancement & product innovation
- Mergers and acquisitions is also a preferred strategy
- Rising investments by private equity & venture capital firms to drive growth
- The major components are therapeutics at 80% & diagnostics, nutrition, pre/probiotics at 20% of market
- US is the largest market, followed by EU


MICROBIOME – VALUE CREATION STRATEGY




EXAMPLE: IBD & MICROBIOME



Before 1960



1960-1979



1980-2008

IRRITABLE BOWEL SYNDROME (IBD)
RELATED TO UNHEALTHY MICROBIOME

- IBD (Irritable Bowel Syndrome) is associated with an unhealthy microbiome and is increasing in developed Western cultures
- Possible Villains dietary changes, cultural changes, use of antibiotics
- Treatments include developing healthy microbiome, dietary changes, healthy life style

MICROBIOME – POSSIBLE ACQUISITION EXAMPLES

MICROBIOME THERAPEUTICS

www.PharmaBiome.com

Gusto Global

www.serestherapeutics.com

eligo.bio/

www.secondgenome.com/

pylumbio.com/

evelobio.com/

www.enterome.fr/

www.rebiotix.com/

www.vedantabio.com/

www.microbiotica.com/

ibtherapeutics.com/

www.c3jtherapeutics.com/

maatpharma.com/

www.kallyope.com/

finchtherapeutics.com/

<https://azitrainc.com/pipeline/>

ORAL HEALTH



SKIN DISEASE



INTESTINAL HEALTH



DRUG DELIVERY




DIETARY SUPPLEMENTS



GENOMICS



CLINICAL DIAGNOSTICS



DIAGNOSTICS, DEVICES & ANALYTICS

metabiomics.com/

ubiome.com

www.respherabio.com/

www.proteus.com/

www.InOutBiome.com

www.cosmosid.com/

www.epibiome.com/

PRE & PROBIOTICS, NUTRITION & DIET

Biocollectives

Microbiome Therapeutics

www.viome.com/

www.evolvebiosystems.com/

www.daytwo.com/


www.thryveinside.com/

www.amplemeal.com/

www.zanduayurveda.com/

WOUND CARE

WOUND CARE - MARKET



Addressable Market	USD 22bn
Key Markets	US followed by EU
CAGR	6%
Growth Driver	<ul style="list-style-type: none"> • Aging population • Rising incidences of diabetes, obesity and other chronic conditions • Increasing surgical interventions leading to acute wound care • Growing awareness of active wound products • Increasing number of seniors living in long-term care facilities

WOUND CARE – ACQUISITION EXAMPLES

1

WOUND ANALYTICS

The Swiss based company aims to reduce healthcare costs by providing affordable, real-time, diagnostic imaging information for predictive wound management and post-surgical wound infection monitoring at clinical quality levels. The company has developed a proven, non-invasive approach, that uses portable, low-cost imaging system and machine learning techniques to measure and visualize the wounds response to thermal stimulation to monitor the progress of wounds.

2

BASIC WOUND CARE COMPANIES

The US based company, is a supplier of custom wound care dressing to wound care companies with custom formulated hydrocolloids. The company has advanced Wound Care production facility to delivers products with consistent, superior quality—made in the United States.

The Swiss based company is the global leader in medical fabrics & knitwear. Customers around the world include pharmacies, chemists, orthopedic and medical specialist stores as well as doctors and hospitals.

3

ADVANCED WOUND CARE COMPANIES

The German company develop cellular-based therapies for unmet medical needs and provide doctors with autologous stem cells being capable to repair and regenerate injured/diseased tissue. The technology has been granted multiple patents in Europe, USA, Japan.

The Swiss company is focus primarily on research and development of new and innovative medical therapies for severe wound-healing as is the case Diabetes. The company has been granted multiple patents.

4

DIGITAL WOUND CARE & SERVICE PROVIDERS

The UK company is a specialist healthcare technology company, dedicated to selling, marketing and supporting innovative technologies and transformation solutions for healthcare innovation. The areas of areas of focus on health innovation in wound management, long term conditions, patient empowerment, self-management and health informatics.

We are happy to elaborate further!

Please ask for further information:

Stefan Nolte

E: stefan.nolte@shandaconsult.com

T: +357 222 72 300

